Bristol Vanlev Second-Line Hypertension Use To Be Reviewed By FDA Cmte.
Bristol-Myers Squibb will ask an FDA advisory committee to recommend Vanlev for a second line hypertension indication, Exec VP Donald Hayden told the Goldman Sachs healthcare conference June 13 in Laguna Niguel, Calif
You may also be interested in...
Bristol-Myers Squibb's Vanlev OCTAVE data suggest that the review of the antihypertensive candidate will focus on a potential second-line indication to the ACE inhibitor enalapril
Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011